Your session is about to expire
← Back to Search
LGK974 for Cancer
Study Summary
This trial is testing a new drug called LGK974 to see if it is safe and effective in treating adults with cancer that has progressed despite standard therapy or for which no effective standard therapy exists.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a specific type of skin cancer eligible for a certain treatment.I do not have any cancer other than the one being treated in this study.I have been diagnosed with osteoporosis or osteopenia.I have had a recent bone fracture or a fracture caused by disease.My heart does not function properly.I have a stomach or intestine problem that affects how my body absorbs medicine.I have brain metastases that have not been treated.My cancer worsened after anti-PD-1 therapy, so I can try LGK974 with PDR001.You have an ongoing autoimmune disease or severe allergic reactions to other monoclonal antibodies.You have certain abnormal test results as outlined in the study plan.My advanced cancer has worsened despite treatment, or there's no effective treatment for it.My cancer has specific genetic changes approved by Novartis.My cancer is B-RAF mutant colorectal or pancreatic.
- Group 1: LGK974
- Group 2: LGK974 in combination with PDR001
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this particular clinical trial the inaugural experiment of its genre?
"Since 2011, there have been 27 active trials for LGK974 conducted in 35 countries and 122 cities. This is due to Novartis Pharmaceuticals sponsoring the first trial of 185 patients back in 2011 which ultimately lead to Phase 1 drug approval."
What potential risks or side effects have been identified regarding LGK974?
"Despite limited evidence of efficacy and safety, our assessment at Power has placed LGK974 on the low end of the scale with a score of 1."
Are there any historical precedents for LGK974's use in medical experiments?
"LGK974 was first trialled at UCLA School of Medicine in 2011, and 21 studies have been concluded since then. There are now 27 ongoing clinical trials with a notable portion being conducted from Montreal, Quebec."
What is the current capacity for participants in this experiment?
"This clinical trial, backed by Novartis Pharmaceuticals, necessitates 185 participants who fit the pre-determined criteria. It will be based in Montreal and Houston, with two sites respectively located at Novartis Investigative Site and University of Texas/MD Anderson Cancer Center MD Anderson 2."
Are there any open vacancies remaining in the clinical trial?
"The details hosted on clinicaltrials.gov demonstrate that this research study is currently accepting participants, having been initially published in December 2011 and last updated at the end of September 2022."
Are there ample research centers implementing this project in North America?
"Participating in this medical research is 5 sites, including Novartis Investigative Site located in Montreal, University of Texas/MD Anderson Cancer Center MD Anderson 2 and Sidney Kimmel Comprehensive Cancer Center Johns Hopkins situated in Houston and Baltimore respectively. A further 5 locations are also engaging with the clinical trial."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger